Dutch Aiosyn secures 2.4M funding to scale AI-powered cancer diagnostics

Nijmegen, the Netherlands – Aiosyn, a Dutch medical software company specializing in AI-powered pathology, has successfully closed a €2.4 million funding round. Participating investors are TNO Ventures, Oost NL, LUMO Labs, and Health Innovations. Alongside the funding, Aiosyn also announced a new strategic partnership with TNO, the Netherlands’ largest research and technology organization. The new funding and partnership will enable Aiosyn to accelerate the development and rollout of its AI-driven diagnostic solutions, aimed at improving cancer care through more efficient and precise pathology workflows.

The rapid evolution of AI in healthcare presents a unique opportunity to transform pathology. By automating complex diagnostic tasks, Aiosyn’s AI solutions empower pathologists to deliver faster, more consistent results—ultimately improving outcomes for cancer patients. Aiosyn’s algorithms are designed to enhance both the speed and precision of pathology workflows. This helps to reduce healthcare costs and deliver more actionable insights for clinicians. With this funding, Aiosyn will expand its portfolio to include novel AI-powered digital pathology biomarkers and advanced tools for preclinical image analysis.

Patrick de Boer, CEO and co-founder of Aiosyn, explains: “This funding marks a major milestone for Aiosyn and reinforces our mission to bring AI innovation into clinical practice and invest in a new generation of AI algorithms that transform clinical decision-making for cancer patients”.

Sven Bakkes, Founding Partner at LUMO Labs, continues, “The potential of Artificial Intelligence in diagnostics is immense. Aiosyn is a great example of how automating complex diagnostic tasks, can improve care for cancer patients. We are pleased to continue our support to accelerate the development and rollout of their solutions.”

Partnership TNO

The new strategic partnership between Aiosyn and TNO creates powerful synergies: Aiosyn will benefit from TNO’s world-class research facilities and network to accelerate the clinical validation and market readiness of its AI software, while TNO gains access to Aiosyn’s cutting-edge AI expertise to strengthen and innovate its leading position in preclinical contract research services. This collaboration reflects TNO’s evolving role as a strategic investor in key technologies that strengthen both its research capabilities and the Dutch tech ecosystem.

“Aiosyn exemplifies the kind of bold, forward-thinking innovation that TNO is proud to support, delivering on TNO’s strategy to help Dutch tech companies scale globally and lead in key technologies”, said Hans Boumans, Director of TNO Ventures.

About Aiosyn

Aiosyn is a Dutch company that develops AI-powered precision pathology software for cancer and kidney disease. Aiosyn’s solutions are integrated into standard pathology workflows. The Aiosyn team has been built upon more than 20 years of research experience in the field of pathology and is rooted in the pathology practice